Comparing the current results to its competitors, Ventyx Biosciences Inc reported Revenue decrease in the 3 quarter 2025 year on year by 0 %, despite the revenue increase by the most of its competitors of 8.53 %, recorded in the same quarter.
Ventyx Biosciences Inc , despite income growth by most of its competitors recorded a net loss, despite income increase by most of its competitors of 46.06 %
July 29, 2024
Phase 2 Trial of VTX958 Fails to Meet Primary Endpoint in Crohn’s Disease Patients: Implications for Ventyx BiosciencesIn the realm of gastroenterology and inflammatory bowel diseases, the importance of therapeutic options cannot be overstated, particularly in complex conditions such as Crohn s disease. Ventyx Biosciences recently announced the results of its Phase 2 trial for VTX958, a novel therapeutic candidate aimed at addressing the challenges faced by patients with moderately to severely active Crohn’s disease. However, the trial s failure to meet its primary endpoint raises critical questions about its future in the treatment landscape, as well as the potential ramifications for Ventyx as a biop...
June 6, 2024
In a recent development, Ventyx Biosciences (NASDAQ: VTYX) has experienced a significant decline of 20% in its stock value. As a result, shareholders are urged to take notice and reach out to BFA Law for further information regarding an ongoing investigation into the company s Board of Directors. This article aims to shed light on the details of the investigation and the potential implications for the pharmaceutical industry.The Investigation:BFA Law, a renowned investigative law firm, has initiated a thorough examination of Ventyx Biosciences Board of Directors. Shareholders have been encouraged to seek additional information through the firm s official website or by directly contacting BFA Law. The invest...
March 23, 2024
In a recent development, the prestigious law firm Pomerantz LLP has announced the filing of a class action lawsuit against Ventyx Biosciences, Inc. (VTYX) and certain officers. This lawsuit, which has been lodged in the United States District Court for the Southern District of California under docket number 24-cv-00415, involves shareholders who suffered losses on their investment in Ventyx. It focuses on the period between the initial public offering (IPO) conducted on or about October 21, 2021, until November 6, 2023.Facts of the Case:The class action lawsuit encompasses two primary periods: (a) the IPO period, which included the acquisition of Ventyx common stock; and (b) the subsequent period between Oct...
Bullfrog Ai Holdings Inc utilizes artificial intelligence technology to develop and provide advanced solutions for businesses. Their business model focuses on offering AI-powered products and services to help companies optimize their operations and decision-making processes.
MannKind Corporation is a biopharmaceutical company that focuses on the development and commercialization of inhaled therapeutic solutions for patients with diseases such as diabetes and pulmonary arterial hypertension. The company's business model revolves around conducting research and development to create innovative inhalation therapies and gaining regulatory approvals for these treatments. They then market and distribute their products, either directly or through partnerships, to healthcare providers and patients worldwide.
Kiniksa Pharmaceuticals International Plc Share Performance
+83.10%
This Year
Kiniksa Pharmaceuticals International Plc
Profile
Kiniksa Pharmaceuticals Ltd is a biopharmaceutical company focused on developing and commercializing therapeutics for patients with debilitating diseases and unmet medical needs. Their business model revolves around identifying potential drug candidates, conducting rigorous research and development, and ultimately bringing these drugs to market to provide innovative treatment options. They generate revenue through the sale of their products and collaborations with other companies for the development and commercialization of their therapies.
Puma Biotechnology Inc operates as a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for the treatment of cancer. Their business model revolves around identifying promising preclinical and clinical drug candidates, conducting rigorous research and development, and seeking regulatory approval for their products. Puma Biotechnology Inc strives to effectively market and distribute their approved therapeutics to provide patients with potentially life-saving treatment options.
Sources:
Ventyx Biosciences Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Ventyx Biosciences Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
